Welcome to HitGen

Investors

688222
RMB
  • Highest
  • Lowest
  • Volume
  • Amount
Up to   Beijing time. There is 15-minute delay in the quoted price.

Stock Information

Basic Information

HitGen Inc. (SSE: 688222.SH), is a drug discovery research company with headquarters in Chengdu, China, and subsidiaries in Cambridge, UK and Houston, USA. HitGen has established leading technology platforms to enable the discovery and optimization of small molecules and nucleic acid-based drugs. Our key technology platforms include world-leading DNA-encoded library technology (DEL), fragment-based drug discovery and structure-based drug design technologies (FBDD/SBDD), as well as the emerging technology platforms for oligonucleotide-based therapeutics (OBT), and targeted protein degradation technology (TPD). Through our diverse and flexible business models, we have built up collaboration partnership with several hundred biopharmaceutical research organizations worldwide. HitGen has multiple programmes from early discovery to clinical trial stage.

Announcements

The Board Office is in charge of the information disclosure and investor relations. The secretary of the board is Shiwei Geng.

Tel:

+86 28 85197385

E-mail:

investors@hitgen.com

info@hitgen.com

We use cookies to provide a better web experience.
By using our site, you acknowledge our use of cookies and please read our Cookie Notice for More information